

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
For the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (04-03)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page

1

of

1

Complete if Known

Application Number	09/782,650
Filing Date	February 12, 2001
First Named Inventor	Arnold J. Levine
Art Unit	1632
Examiner Name	Ram R. Shukla

Attorney Docket Number

20553D-000611US

RECEIVED
JUN 6 2003
TECH CENTER 1600
2003

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
RRS	AA	US-6,303,573 B1		10/16/2001	Ruoslathi <i>et al.</i>	_____

FOREIGN PATENT DOCUMENTS

Examiner Initials ³	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
RRS	AB	EP	0 721 983	A1	07/17/1996	ZymoGenetics, Inc.	_____	<input type="checkbox"/>
RRS	AC	WO	96/26736	A1	09/06/1996	Ludwig Institute for Cancer Research and Helsinki University Licensing Ltd.	_____	<input type="checkbox"/>
	AD	WO	97/10507	A1	03/20/1997	La Jolla Cancer Research Foundation	1	<input type="checkbox"/>
	AE	WO	97/12519	A1	04/10/1997	St. Elizabeth's Medical Center of Boston, Inc.	_____	<input type="checkbox"/>
RRS							_____	<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ²
RRS	AF	Arora <i>et al.</i> , 1999, "Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells," <i>Cancer Research</i> 59:18-188					
	AG	Banai <i>et al.</i> , 1994, "Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs," <i>Circulation</i> 89(5):2183-2189					
	AH	Billups <i>et al.</i> , 1995, "Expression of E-selectin mRNA during ischemia/reperfusion injury," <i>J. Lab. Clin. Med.</i> 125:626-633					
	AI	Bowles <i>et al.</i> , 1997, "Prospects for adenovirus-mediated gene therapy of inherited diseases of the myocardium," <i>Cardiovascular Research</i> 35:422-430					
RRS	AJ	Deckert <i>et al.</i> , 1998, "The complete genome of the hyperthermophilic bacterium <i>Aquifex aeolicus</i> ," <i>Nature</i> 392:353-358					

Examiner Signature	RRS	Date Considered	9/15/03
--------------------	-----	-----------------	---------


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WC 9058197 v1



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page

of

1

Complete if Known

Application Number	09/782,650
Filing Date	February 12, 2001
First Named Inventor	Arnold J. Levine
Art Unit	1632
Examiner Name	Ram R. Shukla

Attorney Docket Number

20553D-000611US

RECEIVED
JUN 02 2003
TECH CENTER 1600/2300

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RMS	AK	Indolfi and Chiariello, 1998, "Gene therapy for cardiovascular disorders," <i>Cardiologia</i> 43(4):365-373	
	AL	Isner <i>et al.</i> , 1996, "Clinical evidence of angiogenesis after arterial gene transfer of phVEGF ₁₆₅ in patient with ischaemic limb," <i>Lancet</i> 348:370-374	
	AM	Knight and Fox, 1995, "The vicious circle of ischemic left ventricular dysfunction," <i>Am. J. Cardiol.</i> 75:10E-15E	
	AN	Korthuis <i>et al.</i> , 1994, "Role of neutrophil-endothelial cell adhesion in inflammatory disorders," <i>Journal of Critical Care</i> 9(1):47-71	
	AO	Kukielka <i>et al.</i> , 1995, "Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium," <i>Molecular and Cellular Biochemistry</i> 147:5-12	
	AP	Lefer and Lefer, 1993, "Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock," <i>Annu. Rev. Pharmacol. Toxicol.</i> 33:71-90	
	AQ	Losordo <i>et al.</i> , 1998, "Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF ₁₆₅ as sole therapy for myocardial ischemia," <i>Circulation</i> 98:2800-2804	
	AR	Ma <i>et al.</i> , 1992, "Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion,"	
	AS	Marche <i>et al.</i> , 1997, "Pharmacologic treatment of atherosclerosis: beyond lipid-lowering therapy," <i>International Journal of Cardiology</i> 62(Suppl. 2):S17-S22	
	AT	Meredith <i>et al.</i> , 1993, "Role of endothelium in ischemic coronary syndromes," <i>Am. J. Cardiol.</i> 72:27C-32C	
	AU	Rader, D. J., 1997, "Gene therapy for atherosclerosis," <i>Int. J. Clin. Lab. Res.</i> 27:35-43	
	AV	Scalia <i>et al.</i> , 1996, "Myocardial protection by N,N,N-trimethylsphingosine in ischemia reperfusion injury is mediated by inhibition of P-selectin," <i>Journal of Leukocyte Biology</i> 59:317-324	
	AW	Schachter, M., 1997, "Calcium antagonists and atherosclerosis," <i>International Journal of Cardiology</i> 62(Suppl. 2):S9-S15	
RMS	AX	Schachter, M., 1997, "Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers," <i>International Journal of Cardiology</i> 62(Suppl. 2):S85-S90	

Examiner Signature	RMS	Date Considered	9/15/03
--------------------	-----	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WC 9058197 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page

3

of

1

Complete if Known

Application Number	09/782,650
Filing Date	February 12, 2001
First Named Inventor	Arnold J. Levine
Art Unit	1632
Examiner Name	Ram R. Shukla

Attorney Docket Number

20553D-000611US

RECEIVED
JUN 8 2003
TECH CENTER 1800/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RJS	AY	Seccombe and Schaff, 1995, "Coronary artery endothelial function after myocardial ischemia and reperfusion," <i>Ann. Thorac. Surg.</i> 60:778-788	
	AZ	Simari and Nabel, 1996, "Genetic therapy," <i>Semin. Intervent. Cardiol.</i> 1:77-83	
	BA	Somanchi <i>et al.</i> , 1998, "Chlamydomonas reinhardtii cDNAs upregulated in low-CO ₂ conditions: expression and analyses," <i>Can. J. Bot.</i> 76:1003-1009	
	BB	Trost <i>et al.</i> , 1998, "Protection against myocardial dysfunction after a brief ischemic period in transgenic mice expressing inducible heat shock protein 70," <i>J. Clin. Invest.</i> 101:855-862	
	BC	Weyrich <i>et al.</i> , 1995, "Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium," <i>J. Leukoc. Biol.</i> 57:45-55	
RJS	BD	Youker <i>et al.</i> , 1994, "Molecular evidence for induction of intracellular adhesion molecule-1 in the viable border zone associated with ischemia-reperfusion injury of the dog heart," <i>Circulation</i> 89:2736-2746	

Examiner Signature	RJS	Date Considered	9/15/03
--------------------	-----	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WC 9058197 v1